title: Primary focal hyperhidrosis: scope of the problem.
abstract: Focal hyperhidrosis (HH) can cause debilitating reductions in the physical and emotional quality of life (QOL) of patients, which can result in numerous restrictions of a patient's personal and professional lifestyle and activities. A variety of treatment options are available for primary focal HH, including topical and oral agents, tap water iontophoresis (TWI), botulinum toxin type A (BTX-A), and surgery. Studies evaluating BTX-A (Botox) treatment for palmar, plantar, and facial HH reveal that BTX-A provides effective treatment of primary focal HH, with a reasonable duration of effect, and has a good safety profile. Physicians should understand the impact of focal HH and the need to stay abreast of the available treatment options to provide the best care for patients.
authors.affiliation: Department of Dermatology, Saint Louis University, Missouri, USA.
authors.forename: Dee Anna
authors.initials: DA
authors.lastname: Glaser
authors.forename: Adelaide A
authors.initials: AA
authors.lastname: Hebert
authors.forename: David M
authors.initials: DM
authors.lastname: Pariser
authors.forename: Nowell
authors.initials: N
authors.lastname: Solish
mesh_terms: D051520:Antiperspirants / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D006945:Hyperhidrosis / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D007478:Iontophoresis / Q000379:methods; D011788:Quality of Life; D013562:Sympathectomy
chemical_list: D051520:Antiperspirants; D018680:Cholinergic Antagonists; D019274:Botulinum Toxins, Type A